{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wei J"],"funding":["National Natural Science Foundation of China"],"pagination":["792-804"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8115146"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(4)"],"pubmed_abstract":["Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative refere"],"journal":["Cellular & molecular immunology"],"pubmed_title":["Clinical development of CAR T cell therapy in China: 2020 update."],"pmcid":["PMC8115146"],"funding_grant_id":["81830002","31991171"],"pubmed_authors":["Wu Z","Zhu J","Guo Y","Bo J","Han W","Wei J","Wang Y","Zhang B"],"additional_accession":[]},"is_claimable":false,"name":"Clinical development of CAR T cell therapy in China: 2020 update.","description":"Chimeric antigen receptor (CAR) T-cell therapy has achieved significant success in the treatment of hematological malignancies. In recent years, fast-growing CAR T clinical trials have actively explored their potential application scenarios. According to the data from the clinicaltrials.gov website, China became the country with the most registered CAR T trials in September 2017. As of June 30, 2020, the number of registered CAR T trials in China has reached 357. In addition, as many as 150 other CAR T trials have been registered on ChiCTR. Although CAR T therapy is flourishing in China, there are still some problems that cannot be ignored. In this review, we aim to systematically summarize the clinical practice of CAR T-cell therapy in China. This review will provide an informative refere","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Apr","modification":"2026-05-09T09:48:18.107Z","creation":"2025-04-03T21:33:30.039Z"},"accession":"S-EPMC8115146","cross_references":{"pubmed":["32999455"],"doi":["10.1038/s41423-020-00555-x"]}}